WORLD-SURF-LEAGUE
Today the World Surf League and Corona announced a multi-year partnership agreement through 2018, making Corona the Official Beer of the World Surf League globally, with the exception of the U.S. market.
“2015 was the single biggest year in surfing history across every major metric we measure, and we are thrilled that Corona – one of the Top 10 most valuable beer brands in the world according to BrandZ 2015 – has chosen to partner with us,” said Mark Noonan, Global Chief Commercial Officer of the World Surf League. “Corona’s aspirational lifestyle is a perfect complement to the WSL, and we are extremely proud to have them join our group of world class partners.”
The WSL and Corona will work together on consumer and customer activations in all key markets aligning Corona’s authentic and unpretentious lifestyle with the World Surf League’s mission of putting the world’s best surfers on the world’s best waves. Corona will engage surf fans through compelling original content, exciting on-site activations like the Corona Sunsets festivals, and corporate social responsibility initiatives at some of the most exotic and remote locations on the planet.
“Corona has been popular with surfers since the early 1980s, when surfers first discovered the point breaks of Baja and regularly enjoyed a crisp, refreshing Corona after catching the waves. We see The World Surf League as a great ambassador for our brand and the Corona lifestyle,” said Global VP Corona Marcel Marcondes. “Corona reminds us all to take a step back, reconnect to our essential nature and enjoy moments outside. This partnership with the WSL creates an abundance of such special moments in the most beautiful settings all year long. We believe the WSL provides us with a valuable opportunity to connect with the WSL’s growing community and LDA fans that are inspired by the surf lifestyle.”
Corona will partner with WSL Championship Tour surfers Coco Ho, Alejo Muniz, Matt Wilkinson and Julian Wilson. At each stop of the WSL Championship Tour, Corona will help ensure the experience of fans is unforgettable. Key markets for brand activations in 2016 will include Australia, Brazil, South Africa and France.
The 2016 Samsung Galaxy World Championship Tour begins with the Quiksilver Pro in Australia, kicking-off on March 10. Fans can catch all the live action by going to worldsurfleague.com or by downloading the free app in either the iTunes store or Google Play.
About The World Surf League
The World Surf League (WSL), formerly the Association of Surfing Professionals (ASP), is dedicated to celebrating the world’s best surfing on the world’s best waves through a variety of best-in-class audience platforms. The League, headquartered in Santa Monica, is a truly global sport with regional offices in Australasia, Africa, North America, South America, Hawaii, Japan and Europe.
The WSL has been championing the world's best surfing since 1976, running global events across the Samsung Galaxy Men's and Women's Championship Tours, the Big Wave Tour, Qualifying Series, Junior and Longboard Championships, as well as the WSL Big Wave Awards. The League possesses a deep appreciation for the sport's rich heritage while promoting progression, innovation and performance at the highest levels.
Showcasing the world's best surfing on its digital platform at WorldSurfLeague.com as well as the free WSL app, the WSL has a passionate global fan base with millions tuning in to see world-class athletes like Mick Fanning, John John Florence, Stephanie Gilmore, Greg Long, Gabriel Medina, Carissa Moore, Makua Rothman, Kelly Slater, Adriano de Souza and more battle on the most unpredictable and dynamic field of play of any sport in the world.
For more information, please visit WorldSurfLeague.com .
About Corona
Corona is the leading beer brand in Mexico, the 6th most valuable beer brand in the world*, and the most popular Mexican beer worldwide, with sales in more than 120 countries. Corona Extra was first brewed in 1925 at the Cervecería Modelo in Mexico City. Ten years after its launch, Corona became the best-selling beer in Mexico, and today continues to stand for Mexican pride around the world. Follow global Corona on Instagram: @corona
View source version on businesswire.com: http://www.businesswire.com/news/home/20160309006234/en/
Contact:
World Surf League
Patty Smith, 310-804-2721
psmith@worldsurfleague.com
or
Corona
Karen
Couck
karencouck@ab-inbev.com
or
Kathleen
Van Boxelaer
kathleen.vanboxelaer@ab-inbev.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom